Two people who received Pfizer’s respiratory syncytial virus (RSV) vaccine during a clinical trial were later diagnosed with Guillain-Barre syndrome, and the US Food and Drug Administration has asked Pfizer to conduct a safety study if the shot is approved, according to agency documents released Friday.Read More
Gain insights, receive dynamic opportunities directly to your inbox. Sign up now…
Catalyzing Investor Engagement, InvestorHyve employs cutting-edge digital marketing solutions, advanced analytics, and an all-encompassing marketing and communications platform to revolutionize corporate interactions with stakeholders. Join us at InvestorHyve and step confidently into the future of corporate engagement
Ready to revolutionize your investor engagement strategy? Join InvestorHyve today and unlock a world of seamless connectivity, personalized interactions, and empowered investor relationships that drive success.
Copyright © 2024. All Rights Reserved.
